Phibro Animal Health Corp (NASDAQ:PAHC) Given Consensus Recommendation of “Hold” by Analysts

Shares of Phibro Animal Health Corp (NASDAQ:PAHC) have received a consensus recommendation of “Hold” from the ten analysts that are presently covering the stock, MarketBeat.com reports. Two research analysts have rated the stock with a sell recommendation, four have assigned a hold recommendation, one has issued a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month target price among brokers that have covered the stock in the last year is $26.60.

A number of equities research analysts have issued reports on PAHC shares. Morgan Stanley upgraded Phibro Animal Health from an “underweight” rating to an “equal” rating and boosted their price target for the company from $21.00 to $30.00 in a research note on Thursday, September 5th. They noted that the move was a valuation call. TheStreet downgraded Phibro Animal Health from a “b-” rating to a “c+” rating in a research note on Tuesday, September 10th. BidaskClub upgraded Phibro Animal Health from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, November 27th. Bank of America cut their price target on Phibro Animal Health from $29.00 to $18.00 and set an “underperform” rating for the company in a research note on Thursday, August 29th. Finally, Barclays cut their price target on Phibro Animal Health from $25.00 to $18.00 and set an “underweight” rating for the company in a research note on Thursday, August 29th.

NASDAQ PAHC traded up $0.50 during trading hours on Tuesday, hitting $24.56. The company’s stock had a trading volume of 102,429 shares, compared to its average volume of 159,040. Phibro Animal Health has a 12 month low of $20.00 and a 12 month high of $36.98. The company’s 50 day simple moving average is $23.27 and its two-hundred day simple moving average is $26.39. The company has a market cap of $973.30 million, a P/E ratio of 18.23, a price-to-earnings-growth ratio of 6.82 and a beta of 0.82. The company has a debt-to-equity ratio of 1.84, a current ratio of 3.21 and a quick ratio of 1.77.

Phibro Animal Health (NASDAQ:PAHC) last released its quarterly earnings data on Monday, November 4th. The company reported $0.19 EPS for the quarter, missing the consensus estimate of $0.24 by ($0.05). Phibro Animal Health had a return on equity of 25.52% and a net margin of 4.99%. The business had revenue of $190.00 million during the quarter, compared to the consensus estimate of $199.22 million. During the same quarter in the previous year, the business posted $0.39 earnings per share. Phibro Animal Health’s quarterly revenue was down 5.0% compared to the same quarter last year. As a group, research analysts predict that Phibro Animal Health will post 1.1 earnings per share for the current fiscal year.

The company also recently declared a quarterly dividend, which will be paid on Wednesday, December 18th. Shareholders of record on Wednesday, November 27th will be paid a dividend of $0.12 per share. The ex-dividend date is Tuesday, November 26th. This represents a $0.48 dividend on an annualized basis and a dividend yield of 1.95%. Phibro Animal Health’s dividend payout ratio is currently 31.37%.

Institutional investors have recently added to or reduced their stakes in the business. FNY Investment Advisers LLC grew its stake in shares of Phibro Animal Health by 73.3% during the 2nd quarter. FNY Investment Advisers LLC now owns 1,040 shares of the company’s stock valued at $33,000 after purchasing an additional 440 shares during the period. Financial Gravity Wealth Inc. bought a new position in shares of Phibro Animal Health during the 2nd quarter valued at approximately $38,000. Zurcher Kantonalbank Zurich Cantonalbank grew its stake in shares of Phibro Animal Health by 74.5% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,361 shares of the company’s stock valued at $29,000 after acquiring an additional 581 shares during the period. Marshall Wace North America L.P. grew its stake in shares of Phibro Animal Health by 12.4% during the 2nd quarter. Marshall Wace North America L.P. now owns 7,119 shares of the company’s stock valued at $226,000 after acquiring an additional 786 shares during the period. Finally, Oppenheimer Asset Management Inc. grew its stake in shares of Phibro Animal Health by 3,930.5% during the 2nd quarter. Oppenheimer Asset Management Inc. now owns 7,537 shares of the company’s stock valued at $240,000 after acquiring an additional 7,350 shares during the period. Institutional investors and hedge funds own 49.94% of the company’s stock.

About Phibro Animal Health

Phibro Animal Health Corporation operates as a diversified animal health and mineral nutrition company primarily in the United States. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets products for a range of food animals, including poultry, swine, beef and dairy cattle, and aquaculture.

Further Reading: What is a Real Estate Investment Trust (REIT)?

Analyst Recommendations for Phibro Animal Health (NASDAQ:PAHC)

Receive News & Ratings for Phibro Animal Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Phibro Animal Health and related companies with MarketBeat.com's FREE daily email newsletter.